Urocortin ameliorates diabetic nephropathy in obese db/db mice

British Journal of Pharmacology

Volumn 154, Issue 5, 2008, Pages 1025-1034

  Li, X ^a   Hu, J ^a   Zhang, R ^a   Sun, X ^b   Zhang, Q ^b   Guan, X ^a   Chen, J ^a   Zhu, Q ^b   Li, S ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

^b NANJING UNIVERSITY OF CHINESE MEDICINE   (China)

Author keywords

Diabetic nephropathy; Extra cellular matrix; Urocortin

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ASTRESSIN; CONNECTIVE TISSUE GROWTH FACTOR; CREATININE; MALONALDEHYDE; SORBITOL; SUPEROXIDE DISMUTASE; TRANSFORMING GROWTH FACTOR BETA1; UROCORTIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DRUG ANTAGONISM; DRUG MECHANISM; ENZYME ACTIVITY; EXTRACELLULAR MATRIX; FOOD INTAKE; GENE OVEREXPRESSION; GLUCOSE BLOOD LEVEL; INSULIN BLOOD LEVEL; KIDNEY HOMOGENATE; MOUSE; NONHUMAN; OBESITY; PRIORITY JOURNAL; RAT; UREA NITROGEN BLOOD LEVEL; WEIGHT REDUCTION;

ANIMALS; BLOOD GLUCOSE; BLOOD UREA NITROGEN; BODY WEIGHT; CELL LINE; CREATININE; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DISEASE MODELS, ANIMAL; EATING; EXTRACELLULAR MATRIX; FEMALE; GLYCOSYLATION END PRODUCTS, ADVANCED; IMMEDIATE-EARLY PROTEINS; INSULIN; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; KIDNEY; MALE; MALONDIALDEHYDE; MESANGIAL CELLS; MICE; MICE, INBRED C57BL; MICE, MUTANT STRAINS; OBESITY; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, CORTICOTROPIN-RELEASING HORMONE; SORBITOL; SUPEROXIDE DISMUTASE; TIME FACTORS; TRANSFORMING GROWTH FACTOR BETA1; UROCORTINS;

EID: 46249094420     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1038/bjp.2008.155     Document Type: Article

References (47)

1. Ahn JD, Morishita R, Kaneda Y, Kim HJ, Kim YD, Lee HJ et al. (2004). Transcription factor decoy for AP-1 reduces mesangial cell proliferation and extracellular matrix production in vitro and in vivo. Gene Therapy 11: 916-923.
2. Bilous RW, Mauer SM, Sutherland DE, Steffes MW (1989). Mean glomerular volume and rate of development of diabetic nephropathy. Diabetes 38: 1142-1147.
3. Brownlee M (2001). Biochemistry and molecular cell biology of diabetic complications. Nature 414: 813-820.
4. Brownlee M, Cerami A, Vlassara H (1988). Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N Engl J Med 318: 1315-1321.
5. Charalampopoulos I, Androulidaki A, Minas V, Chatzaki E, Tsatsanis C, Notas G et al. (2006). A Neuropeptide urocortin and its receptors are expressed in rat Kupffer cells. Neuroendocrinology 84: 49-57.
6. Chen A, Brar B, Choi CS, Rousso D, Vaμghan J, Kuperman Y et al. (2006). Urocortin 2 modulates glucose utilization and insulin sensitivity in skeletal muscle. Proc Natl Acad Sci USA 103: 16580-16585.
7. Dan Q, Wong R, Chung SK, Chung SS, Lam KS (2004). Interaction between the polyol pathway and non-enzymatic glycation on aortic smooth muscle cell migration and monocyte adhesion. Life Sci 76: 445-459.
8. Donaldson CJ, Sutton SW, Perrin MH, Corrigan AZ, Lewis KA, Rivier JE et al. (1996). Cloning and characterization of human urocortin. Endocrinology 137: 2167-2170.
9. Dunlop M (2000). Aldose reductase and the role of the polyol pathway in diabetic nephropathy. Kidney Int Suppl 77: S3-S12.
10. Fekete EM, Zorrilla EP (2007). Physiology, pharmacology, and therapeutic relevance of urocortins in mammals: ancient CRF paralogs. Front Neuroendocrinol 28: 1-27.
11. Forbes JM, Fukami K, Cooper ME (2007). Diabetic nephropathy: where hemodynamics meets metabolism. Exp Clin Endocrinol Diabetes 115: 69-84.
12. Fruehwald-Schultes B, Kern W, Beyer J, Forst T, Pfützner A, Peters A (1999). Elevated serum leptin concentrations in type 2 diabetic patients with microalbuminuria and macroalbuminuria. Metabolism 48: 1290-1293.
13. Guhua Z, Cai L, Lu C (2004). Advanced glycation end-products induce connective tissue growth factor-mediated renal fibrosis predominantly through transforming growth factor β-independent pathway. Am J Pathol 165: 2033-2043.
14. Gupta S, Chough E, Daley J, Oates P, Tornheim K, Ruderman NB et al. (2002). Hyperglycemia increases endothelial superoxide that impairs smooth muscle cell Na+-K+-ATPase activity. Am J Physiol Cell Physiol 282: C560-C566.
15. Hisashi M, Yoshihiro M, Kazutomo S, Kiyoshi M, Masashi M, Kazuwa N et al. (2006). Shin-ichi S altered gene expression related to glomerulogenesis and podocyte structure in early diabetic nephropathy of db/db mice and its restoration by pioglitazone. Diabetes 55: 2747-2756.
16. Honjo T, Inoue N, Shiraki R, Kobayashi S, Otsui K, Takahashi M et al. (2006). Endothelial urocortin has potent antioxidative properties and is upregulated by inflammatory cytokines and pitavastatin. J Vasc Res 43: 131-138.
17. Hope PJ, Turnbull H, Farr S, Morley JE, Rice KC, Chrousos GP et al. (2000). Peripheral administration of CRF and urocortin: effect on food intake and the HPA axis in the marsupial Sminthopis crassicaudata. Peptides 21: 669-677.
18. Huang Y, Chan FL, Lau CW, Tsang SY, He GW, Chen ZY et al. (2002). Urocortin-induced endothelium- dependent relaxation of rat coronary artery: role of nitric oxide and K+ channels. Br J Pharmacol 135: 1467-1476.
19. Javor ED, Moran SA, Young JR, Cochran EK, DePaoli AM, Oral EA et al. (2004). Proteinuric nephropathy in acquired and congenital generalized lipodystrophy: baseline characteristics and course during recombinant leptin therapy. J Clin Endocrinol Meta 89: 3199-3207.
20. Kageyama K, Bradbury MJ, Zhao L, Blount AL, Vale WW (1999). Urocortin messenger ribonucleic acid: tissue distribution in the rat and regulation in thymus by lipopolysaccharide and glucocorticoids. Endocrinology 140: 5651-5658.
21. Kastin AJ, Pan W, Akerstrom V, Hackler L, Wang C, Kotz CM (2002). Novel peptide-peptide cooperation may transform feeding behavior. Peptides 23: 2189-2196.
22. Kedziora-Kornatowska K, Szram S, Kornatowski T, Szadujkis-Szadurski L, Kedziora J, Bartosz G (2003). Effect of vitamin E and vitamin C supplementation on antioxidative state and renal glomerular basement membrane thickness in diabetic kidney. Nephron Exp Nephrol 95: e134-e143.
23. Kinney JW, Scrμggs B, Avery DD (2000). Peripheral administration of urocortin suppresses operant responding for food reward. Peptides 22: 583-587.
24. Lenz O, Zheng F, Vilar J, Doublier S, Lupia E, Schwedler S et al. (1998). The inheritance of glomerulosclerosis in mice is controlled by multiple quantitative trait loci. Nephrol Dial Transplant 13: 3074-3078.
25. Li C, Chen P, Vaughan J, Blount A, Chen A, Jamieson PMet al. (2003). Urocortin III is expressed in pancreatic beta-cells and stimulates insulin and glucagon secretion. Endocrinology 144: 3216-3224.
26. Like AA, Lavine RL, Poffenbarger PL, Chick WL (1972). Studies in the diabetic mutant mouse. VI. Evolution of glomerular lesions and associated proteinuria. Am J Pathol 66: 193-224.
27. Liu CN, Yang C, Liu XY, Li S (2005). In vivo protective effects of urocortin on ischemia-reperfusion injury in rat heart via free radical mechanisms. Can J Physiol Pharmacol 83: 459-465.
28. Malone JI, Leavengood H, Peterson MJ, O'Brien MM, Page MG, Aldinger CE (1984). Red blood cell sorbitol as an indicator of polyol pathway activity inhibition by sorbinil in insulin-dependent diabetic subjects. Diabetes 33: 45-49.
29. Mclennan SV, Wang XY, Moreno V, Yue DK, Twigg SM (2004). Connective tissue growth factor mediates high glucose effects on martrix degradation through tissue inhibitor of matrix metalloproteinase type 1: implications for diabetic nephropathy. Endocrinology 145: 5646-5655.
30. Mohora M, Virgolici B, Paveliu F, Lixandru D, Muscurel C, Greabu M (2006). Free radical activity in obese patients with type 2 diabetes mellitus. Rom J Intern Med 44: 69-78.
31. Munch G, Keis R, Wessels A, Riederer P, Bahner U, Heidland A et al. (1997). Determination of advanced glycation end products in serum by fluorescence spectroscopy and competitive ELISA. Eur J Clin Chem Clin Biochem 35: 669-677.
32. Murphy M, Godson C, Cannon S, Kato S, Mackenzie HS, Martin F et al. (1999). Suppression subtractive hybridization identifies high glucose levels as a stimulus for expression of connective tissue growth factor and other genes in human mesangial cells. J Biol Chem 274: 5830-5834.
33. Natali A, Toschi E, Baldeweg S, Ciociaro D, Favilla S, Sacca L (2006). Clustering of insulin resistance with vascular dysfunction and low-grade inflammation in type 2 diabetes. Diabetes 55: 1133-1140.
34. Nishikawa T, Araki E (2007). Impact of Mitochondrial ROS production in the pathogenesis of diabetes mellitus and its complications. Antioxid Redox Signal 9: 343-353.
35. Park I, Kiyomoto H, Abboud SL, Abboud HE (1997). Expression of transforming growth factor-beta and type IV collagen in early streptozotocin induced diabetes. Diabetes 46: 473-480.
36. Rademaker MT, Charles CJ, Espiner EA, Frampton CM, Lainchbury JG, Richards AM (2005). Four-day urocortin-I administration has sustained beneficial haemodynamic, hormonal, and renal effects in experimental heart failure. Eur Heart J 26: 2055-2062.
37. Rossing P (2006). Diabetic nephropathy: worldwide epidemic and effects of current treatment on natural history. Curr Diab Rep 6: 479-483.
38. Sanz E, Fernandez N, Monge L, Climent B, Dieguez G, Garcia-Villalon AL (2003). Relaxation by urocortin of rat renal arteries: effects of diabetes in males and females. Cardiovasc Res 58: 706-711.
39. Sharma K, McCue P, Dun SR (2003). Diabetic kidney disease in db/db mouse. Am J Physiol Renal Physiol 284: F1138-F1144.
40. Smedsrod B, Melkko J, Araki N, Sano H, Horiuchi S (1997). Advanced glycation end products are eliminated by scavenger-receptor-mediated endocytosis in hepatic sinusoidal Kupffer and endothelial cells. Biochem J 322: 567-573.
41. Starkey JM, Haidacher SJ, LeJeune WS, Zhang X, Tieu BC, Choudhary S et al. (2006). Diabetes-induced activation of canonical and noncanonical nuclear factor-κB pathways in renal Cortex. Diabetes 55: 1252-1259.
42. Sugimoto H, Grahovac G, Zeisberg M, Kalluri R (2007). Renal fibrosis and glomerulosclerosis in a new mouse model of diabetic nephropathy and its regression by bone morphogenic protein-7 and advanced glycation end product inhibitors. Diabetes 56: 1825-1833.
43. Sun SZ, Wang Y, Li Q, Tian YJ, Liu MH, Yu YH (2006). Effects of benazepril on renal function and kidney expression of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 in diabetic rats. Chin Med J (Engl) 119: 814-821.
44. Umezono T, Toyoda M, Kato M, Miyauchi M, Kimura M, Maruyama M et al. (2006). Glomerular expression of CTGF, TGF-beta 1 and type IV collagen in diabetic nephropathy. J Nephrol 19: 751-757.
45. Vaughan J, Donaldson C, Bittencourt J, Perrin MH, Lewis K, Sutton S et al. (1995). Urocortin, a mammalian neuropeptide related to fish urotensin I and to corticotropin-releasing factor. Nature 378: 287-292.
46. Yamagishi S, Inagaki Y, Okamoto T, Amano S, Koga K, Takeuchi M et al. (2002). Advanced glycation end product-induced apoptosis and overexpression of vascular endothelial growth factor and monocyte chemoattractant protein-1 in human-cultured mesangial cells. J Biol Chem 277: 20309-20315.
47. Yang C, Xu Y, Mendez T, Wang F, Yang Q, Li S (2006). Effects of intravenous urocortin on angiotensin-converting enzyme in rats. Vascul Pharmacol 44: 238-246.